Posted by Michael Wonder on 26 Jul 2024
Arcutis submits supplemental new drug application for Zorvye (roflumilast) foam to the FDA for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over
23 July 2024 - Once daily Zorvye foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial.
Arcutis Biotherapeutics today announced the submission of a supplemental new drug application for Zorvye (roflumilast) foam 0.3%, a once daily, next generation phosphodiesterase-4 inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.
